Litigation Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LTD (D.N.J. 2018)
✉ Email this page to a colleague
SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LTD (D.N.J. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-02-13 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-11-27 |
| Cause | 35:271 Patent Infringement | Assigned To | Stanley R. Chesler |
| Jury Demand | Referred To | Cathy L. Waldor | |
| Parties | EMCURE PHARMACEUTICALS LTD | ||
| Patents | 7,323,493; 8,729,085; 8,883,794; 9,555,027; 9,815,827; 9,907,794 | ||
| Link to Docket | External link to docket | ||
Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LTD (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-10-05 | 131 | Opinion | application, which issued as U.S. Patent No. 7,323,493, Sanofi amended the sole independent claims…intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history…terms in the ‘827 patent and a single term in the ‘794 patent. At issue in the ‘827 patent is the meaning…in Non-patent Document 1.” ‘085 patent, col.2 ll.9-13. The specification identifies Non-patent Document…consolidated patent infringement actions, the parties seek construction of claim terms in U.S. Patent No. 9, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
